Staging for intrahepatic cholangiocarcinoma: Are we getting close to understanding the true tumor biology ?
Menée auprès de 275 patients atteints d'un cholangiocarcinome intrahépatique (âge médian : 65 ans), cette étude évalue, par rapport au système de stadification de l'"American Joint Committee on Cancer", la performance d'un système d'indice, basé sur 5 critères clinico-pathologiques (caractère multifocal de la maladie, extension extra-hépatique, grade de la maladie, atteinte ganglionnaire et âge), pour prédire la survie après une hépatectomie
The worldwide incidence of intrahepatic cholangiocarcinoma (ICC) is increasing, and the oncological outcomes are far from satisfactory. Lack of both an understanding of its tumor biology and a distinct staging system that gives us accurate prognostic value could be the reason for this disappointing outcome. Therefore, there is a need to develop a solid staging system that provides integrated guidance for the treatment of ICC. Historically, the hepatocellular carcinoma staging system had been applied to ICC until the seventh edition of American Joint Committee on Cancer (AJCC) classification was developed.
JAMA Surgery , commentaire, 2016